EX-99.1 2 ex99112312023.htm EX-99.1 Document
Exhibit 99.1
    



Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results
DENVER, February 8, 2024 - Healthpeak Properties, Inc. (NYSE: PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the fourth quarter and full-year ended December 31, 2023.

FOURTH QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS
–Net income of $0.13 per share, Nareit FFO of $0.48 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.36 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 3.6%
–Fourth quarter new and renewal lease executions totaled 1.1 million square feet:
▪Outpatient Medical new and renewal lease executions totaled 743,000 square feet
▪Lab new and renewal lease executions totaled 312,000 square feet
▪Year-to-date 2024 Lab lease executions of 58,000 square feet with an additional 115,000 square feet under signed LOI
–Received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus in South San Francisco
–Commenced two on-campus outpatient developments in our HCA Healthcare ("HCA") development program
–Entered into a new $236 million joint venture through the sale of a 65% interest in the Callan Ridge lab campus in the Torrey Pines submarket of San Diego in January 2024
–Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended December 31, 2023

FULL-YEAR 2023 HIGHLIGHTS
–Net income of $0.56 per share, Nareit FFO of $1.79 per share, FFO as Adjusted of $1.78 per share, AFFO of $1.53 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 4.8%
–Portfolio leasing summary:
▪Full-year outpatient lease executions totaled 4.1 million square feet, with +4% cash releasing spreads on renewals
▪Full-year lab lease executions totaled 985,000 square feet, with +23% cash releasing spreads on renewals
–Development highlights:
▪2023 completions and new starts:
▪Nexus on Grand: Delivered the fully leased, 148,000 square foot, $161 million lab building in South San Francisco
▪Vantage: Delivered the fully leased, 154,000 square foot, $201 million first building of Phase I in South San Francisco
▪Callan Ridge: Completed core and shell work and delivered the space to the tenant for T.I. build out; the fully leased development in Torrey Pines totals 185,000 square feet with an expected total development cost of $146 million
▪HCA Development Program: Commenced construction on two new outpatient developments totaling 192,000 square feet with total expected development costs of $90 million
▪Land bank and future developments:
▪In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife where Healthpeak owns a total of 39 acres
▪In December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus
Page 1

–Issued $750 million of senior unsecured notes at blended yield of approximately 5.35% and weighted average initial maturity of approximately 10 years
–Sold $130 million of non-core properties at an average trailing cash yield of 5.4% and received $205 million of seller financing and other loan repayments
–2023 sustainability and responsible business recognitions include:
▪Received a Green Star rating from the Global Real Estate Sustainability Benchmark (GRESB) and named a constituent in the FTSE4Good Index for the twelfth consecutive year
▪Named to CDP's Leadership band for the eleventh consecutive year, named a constituent in the S&P Global Dow Jones Sustainability N. America Index for the eleventh consecutive year and World Index for the fourth time; and named to the S&P Global Sustainability Yearbook for the ninth consecutive year
▪Named an ENERGY STAR Partner of the Year for the third time
▪Named to Newsweek’s America’s Most Responsible Companies list for the fifth consecutive year
▪Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by IR Magazine and Governance Intelligence
▪Certified a Great Place to Work for the fourth consecutive year; included in The Tennessean Top Workplaces for the second consecutive year; and a Middle Tennessee Top Workplace for the first time
▪Included in Fortune's Best Workplaces in Real Estate list for the second consecutive year
To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.

FOURTH QUARTER COMPARISON
 Three Months Ended December 31, 2023Three Months Ended December 31, 2022
(in thousands, except per share amounts)AmountPer ShareAmountPer Share
Net income, diluted$70,787 $0.13 $6,388 $0.01 
Nareit FFO, diluted263,810 0.48 192,158 0.35 
FFO as Adjusted, diluted252,639 0.46 238,744 0.44 
AFFO, diluted196,622 0.36 194,414 0.36 
FULL-YEAR COMPARISON
 Year Ended
December 31, 2023		Year Ended
December 31, 2022
(in thousands, except per share amounts)AmountPer ShareAmountPer Share
Net income, diluted$304,284 $0.56 $497,792 $0.92 
Nareit FFO, diluted994,574 1.79 904,573 1.66 
FFO as Adjusted, diluted987,708 1.78 950,259 1.74 
AFFO, diluted847,358 1.53 790,296 1.45 
Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "December 31, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.
Page 2

SAME-STORE ("SS") OPERATING SUMMARY
The table below outlines the year-over-year three-month and full-year SS Cash (Adjusted) NOI growth.
Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth
Three MonthFull Year
SS Growth %% of SSSS Growth %% of SS
Lab2.7 %47.1 %3.7 %46.6 %
Outpatient Medical4.3 %41.4 %3.4 %42.0 %
CCRC4.7 %11.5 %15.6 %11.5 %
Total Portfolio3.6 %100.0 %4.8 %100.0 %



Page 3

CALLAN RIDGE LAB CAMPUS JOINT VENTURE SALE
As previously announced, in January 2024, Healthpeak formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a 65% interest in Healthpeak’s fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego.
The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at $236 million, or $1,275 per square foot, and represents a stabilized cash capitalization rate of 5.3% based on the initial annual rental rate of approximately $67 per square foot. At closing, net proceeds to Healthpeak were approximately $130 million. Additionally, the formation of the joint venture reduces Healthpeak's future tenant improvement funding by approximately $20 million.
Healthpeak began construction on the 185,000 square foot Callan Ridge campus in 2021. The two-building campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), through April 2035.
DEVELOPMENT UPDATES
VANTAGE ENTITLEMENTS
As previously announced, in December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab space at the Vantage campus, bringing the combined campus to approximately 1.7 million square feet upon full build out. The additional entitlements represent double the allowable density compared to when Healthpeak originally acquired the land. The long-term nature of the entitlements offers flexibility to deliver the balance of the development in phases to align with market demand.
Strategically located in the heart of South San Francisco and at the doorstep of Genentech’s headquarters, the 20-acre purpose-built lab campus offers tenants a highly amenitized, world-class campus setting with access to multiple modes of transportation including direct access to the Rails-to-Trails pathway, which provides a pedestrian connection to downtown South San Francisco's restaurant and retail corridor, as well as the Caltrain station, which recently completed a multi-year renovation.
Healthpeak is South San Francisco's largest investor-owned landlord with a portfolio that encompasses 4.9 million square feet, including some the submarket's most desirable campuses including The Cove, Portside at Oyster Point, The Shore, Vantage, and Pointe Grand, among others.
OUTPATIENT DEVELOPMENT PROGRAM WITH HCA
During the fourth quarter, Healthpeak added two on-campus outpatient developments with total expected development costs of $90 million to its program with HCA.
•Galen Aurora: 72,000 square foot Class A medical training facility located on HCA’s Medical Center of Aurora hospital campus, a 325-bed acute care hospital in Denver, CO where Healthpeak currently owns three on-campus buildings totaling approximately 165,000 square feet. HCA nursing and professional education affiliates have pre-leased 100% of the development.
•McKinney Medical Center: 120,000 square foot Class A outpatient building on the campus of HCA's Medical City McKinney campus, a 281-bed acute care hospital in McKinney, TX where Healthpeak currently owns two on-campus buildings totaling approximately 120,000 square feet. HCA affiliates have pre-leased approximately 62% of the development for future outpatient services, including oncology, orthopedic, cardiology, wound care, imaging, and other services.
Since 2019, Healthpeak’s development program with HCA has delivered 9 outpatient buildings totaling 785,000 square feet with total development costs of approximately $235 million and is under construction on an additional three buildings totaling 262,000 square feet with total expected development costs of $121 million.
MERGER WITH PHYSICIANS REALTY TRUST AND TERM LOAN UPDATE
As previously announced on October 30, 2023, Healthpeak and Physicians Realty Trust entered into a definitive agreement to combine in an all-stock merger of equals. Each company will hold its respective special meeting of stockholders on February 21, 2024. Subject to Physicians Realty Trust's stockholders approving the proposed merger and Healthpeak's stockholders approving the issuance of Healthpeak common stock in connection with the proposed merger, among other matters, as well as the satisfaction or waiver of customary closing conditions, the transaction is expected to close on March 1, 2024.


Additionally, Healthpeak expects to enter into a new $750 million 5-year unsecured term loan. Proceeds from the term loan are expected to fund the repayment of $210 million of Physicians Realty Trust private placement notes and to be used for general corporate purposes, including transaction costs and repayment of borrowings under Healthpeak's credit facility and commercial paper program. Healthpeak has entered into forward-starting swap agreements to fix the interest rate of the new term loan at approximately 4.5% for the full 5-year term of the loan.
DIVIDEND  
On January 31, 2024, Healthpeak's Board declared a quarterly common stock cash dividend of $0.30 per share to be paid on February 26, 2024, to stockholders of record as of the close of business on February 14, 2024.
2024 OUTLOOK
For full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger:
▪Diluted earnings per common share of $0.07 – $0.13
▪Diluted Nareit FFO per share of $1.54 – $1.60
▪Diluted FFO as Adjusted per share of $1.73 – $1.79
▪Diluted AFFO per share of $1.50 – $1.56
▪Total Portfolio Same-Store Cash (Adjusted) NOI growth of 2.25% – 3.75%
This outlook assumes the merger with Physicians Realty Trust closes on March 1, 2024. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2024. Additionally, the outlook includes estimates for certain merger-related accounting adjustments, which will not be finalized until after the merger closes. For additional details and assumptions underlying this outlook, please see page 40 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.


CONFERENCE CALL INFORMATION
Healthpeak has scheduled a conference call and webcast for Friday, February 9, 2024, at 8:00 a.m. Mountain Time.
The conference call can be accessed in the following ways:
▪Healthpeak’s website: https://ir.healthpeak.com/news-events
▪Webcast: https://events.q4inc.com/attendee/292488797. Joining via webcast is recommended for those who will not be asking questions.
▪Telephone: The participant dial-in number is (800) 715-9871.
An archive of the webcast will be available on Healthpeak's website through February 7, 2025, and a telephonic replay can be accessed through February 15, 2024, by dialing (800) 770-2030 and entering conference ID number 58822.
ABOUT HEALTHPEAK
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.
FORWARD-LOOKING STATEMENTS
Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our proposed merger with Physicians Realty Trust; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2024 Outlook." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; risks associated with the proposed merger transactions with Physicians Realty Trust (the “Mergers”), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers, and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers; our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our


ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; ESG and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and the possibility of a cybersecurity incident or cybersecurity threat affect our information systems or the information systems of our tenants, operators or borrowers; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.
ADDITIONAL INFORMATION AND WHERE TO FIND IT
In connection with the proposed transaction, on December 15, 2023, Healthpeak and Physicians Realty Trust filed with the SEC a registration statement on Form S-4 containing a joint proxy statement/prospectus and other documents regarding the proposed transaction. The joint proxy statement/prospectus contains important information about the proposed transaction and related matters. The Form S-4 was declared effective, and each of Healthpeak and Physicians Realty Trust commenced mailing of the joint proxy statement/prospectus included as part of the Form S-4, on January 11, 2024.
STOCKHOLDERS ARE URGED AND ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEALTHPEAK, PHYSICIANS REALTY TRUST AND THE PROPOSED TRANSACTION.
Investors and security holders of Healthpeak and Physicians Realty Trust are able to obtain free copies of the registration statement, the joint proxy statement/prospectus and other relevant documents filed by Healthpeak and Physicians Realty Trust with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Healthpeak with the SEC are also available on Healthpeak’s website at www.healthpeak.com, and copies of the documents filed by Physicians Realty Trust with the SEC are available on Physicians Realty Trust’s website at www.docreit.com.
PARTICIPANTS IN THE SOLICITATION
Healthpeak, Physicians Realty Trust and their respective directors, trustees and executive officers may be deemed to be participants in the solicitation of proxies from Healthpeak’s stockholders and Physicians Realty Trust’s shareholders in respect of the proposed transaction. Information regarding Healthpeak’s directors and executive officers can be found in Healthpeak’s definitive proxy statement filed with the SEC on March 17, 2023. Information regarding Physicians Realty Trust’s trustees and executive officers can be found in Physicians Realty Trust’s definitive proxy statement filed with the SEC on March 23, 2023.
Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and other relevant documents filed with the SEC in connection with the proposed transaction. These documents are available on the SEC’s website and from Healthpeak and Physicians Realty Trust, as applicable, using the sources indicated above.


NO OFFER OR SOLICITATION
This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
CONTACT
Andrew Johns, CFA
Senior Vice President – Investor Relations
720-428-5400




Healthpeak Properties, Inc.
Consolidated Balance Sheets
In thousands, except share and per share data
December 31,
2023		December 31,
2022
Assets  
Real estate:  
Buildings and improvements$13,329,464 $12,784,078 
Development costs and construction in progress643,217 760,355 
Land and improvements2,647,633 2,667,188 
Accumulated depreciation and amortization(3,591,951)(3,188,138)
Net real estate13,028,363 13,023,483 
Loans receivable, net of reserves of $2,830 and $8,280218,450 374,832 
Investments in and advances to unconsolidated joint ventures782,853 706,677 
Accounts receivable, net of allowance of $2,282 and $2,39955,820 53,436 
Cash and cash equivalents117,635 72,032 
Restricted cash51,388 54,802 
Intangible assets, net314,156 418,061 
Assets held for sale, net117,986 49,866 
Right-of-use asset, net240,155 237,318 
Other assets, net772,044 780,722 
Total assets$15,698,850 $15,771,229 
Liabilities and Equity  
Bank line of credit and commercial paper$720,000 $995,606 
Term loans496,824 495,957 
Senior unsecured notes5,403,378 4,659,451 
Mortgage debt256,097 346,599 
Intangible liabilities, net127,380 156,193 
Liabilities related to assets held for sale, net729 4,070 
Lease liability206,743 208,515 
Accounts payable, accrued liabilities, and other liabilities657,196 772,485 
Deferred revenue905,633 844,076 
Total liabilities8,773,980 8,482,952 
Commitments and contingencies
Redeemable noncontrolling interests48,828 105,679 
Common stock, $1.00 par value: 750,000,000 shares authorized; 547,156,311 and 546,641,973 shares issued and outstanding547,156 546,642 
Additional paid-in capital10,405,780 10,349,614 
Cumulative dividends in excess of earnings(4,621,861)(4,269,689)
Accumulated other comprehensive income (loss)19,371 28,134 
Total stockholders’ equity6,350,446 6,654,701 
Joint venture partners310,998 327,721 
Non-managing member unitholders214,598 200,176 
Total noncontrolling interests525,596 527,897 
Total equity6,876,042 7,182,598 
Total liabilities and equity$15,698,850 $15,771,229 


Healthpeak Properties, Inc.
Consolidated Statements of Operations
In thousands, except per share data
 Three Months Ended
December 31,		Year Ended
December 31,
 2023202220232022
Revenues:
 Rental and related revenues $412,332 $392,245 $1,631,805 $1,541,775 
 Resident fees and services 136,341 125,873 527,417 494,935 
 Interest income 4,979 6,350 21,781 23,300 
 Income from direct financing leases — — — 1,168 
 Total revenues 553,652 524,468 2,181,003 2,061,178 
 Costs and expenses:  
 
 Interest expense 52,784 49,413 200,331 172,944 
 Depreciation and amortization 188,544 179,157 749,901 710,569 
 Operating 224,401 220,492 902,060 862,991 
 General and administrative 21,556 57,872 95,132 131,033 
 Transaction and merger-related costs 14,417 3,217 17,515 4,853 
 Impairments and loan loss reserves (recoveries), net (5,445)3,326 (5,601)7,004 
 Total costs and expenses 496,257 513,477 1,959,338 1,889,394 
 Other income (expense):  
 
 Gain (loss) on sales of real estate, net — (969)86,463 9,078 
 Other income (expense), net 2,600 (587)6,808 326,268 
 Total other income (expense), net 2,600 (1,556)93,271 335,346 
 Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures 59,995 9,435 314,936 507,130 
 Income tax benefit (expense) 11,842 650 9,617 4,425 
 Equity income (loss) from unconsolidated joint ventures 3,558 (156)10,204 1,985 
 Income (loss) from continuing operations 75,395 9,929 334,757 513,540 
 Income (loss) from discontinued operations — 873 — 2,884 
 Net income (loss) 75,395 10,802 334,757 516,424 
Noncontrolling interests’ share in continuing operations(4,451)(4,274)(28,748)(15,975)
 Net income (loss) attributable to Healthpeak Properties, Inc. 70,944 6,528 306,009 500,449 
 Participating securities’ share in earnings (157)(140)(1,725)(2,657)
Net income (loss) applicable to common shares$70,787 $6,388 $304,284 $497,792 
Basic earnings (loss) per common share:
Continuing operations$0.13 $0.01 $0.56 $0.92 
Discontinued operations— 0.00 — 0.00 
Net income (loss) applicable to common shares$0.13 $0.01 $0.56 $0.92 
Diluted earnings (loss) per common share:
Continuing operations$0.13 $0.01 $0.56 $0.92 
Discontinued operations— 0.00 — 0.00 
Net income (loss) applicable to common shares$0.13 $0.01 $0.56 $0.92 
Weighted average shares outstanding:  
Basic547,091 537,992 547,006 538,809 
Diluted547,361 538,396 547,275 539,147 


Healthpeak Properties, Inc.
Funds From Operations
 In thousands, except per share data
 Three Months Ended
December 31,		Year Ended
December 31,
 2023202220232022
Net income (loss) applicable to common shares$70,787 $6,388 $304,284 $497,792 
Real estate related depreciation and amortization188,544 179,157 749,901 710,569 
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures 6,723 8,642 24,800 27,691 
Noncontrolling interests’ share of real estate related depreciation and amortization(4,610)(4,709)(18,654)(19,201)
Loss (gain) on sales of depreciable real estate, net— 986 (86,463)(10,422)
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures — 45 — 134 
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net— — 11,546 12 
Loss (gain) upon change of control, net(1)
— — (234)(311,438)
Taxes associated with real estate dispositions— — — 29 
Nareit FFO applicable to common shares261,444 190,509 985,180 895,166 
Distributions on dilutive convertible units and other2,366 1,649 9,394 9,407 
Diluted Nareit FFO applicable to common shares$263,810 $192,158 $994,574 $904,573 
Diluted Nareit FFO per common share$0.48 $0.35 $1.79 $1.66 
Weighted average shares outstanding - diluted Nareit FFO554,635 543,879 554,559 546,462 
Impact of adjustments to Nareit FFO:
Transaction and merger-related items(2)
$10,842 $3,215 $13,835 $4,788 
Other impairments (recoveries) and other losses (gains), net(3)
(4,407)9,702 (3,850)3,829 
Restructuring and severance-related charges(4)
— 32,749 1,368 32,749 
Casualty-related charges (recoveries), net(5)
(3,424)298 (4,033)4,401 
Recognition (reversal) of valuation allowance on deferred tax assets(6)
(14,194)— (14,194)— 
Total adjustments(11,183)45,964 (6,874)45,767 
FFO as Adjusted applicable to common shares250,261 236,473 978,306 940,933 
Distributions on dilutive convertible units and other2,378 2,271 9,402 9,326 
Diluted FFO as Adjusted applicable to common shares$252,639 $238,744 $987,708 $950,259 
Diluted FFO as Adjusted per common share$0.46 $0.44 $1.78 $1.74 
Weighted average shares outstanding - diluted FFO as Adjusted554,635 545,704 554,559 546,462 
_______________________________________
(1)The year ended December 31, 2022 includes a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated lab buildings in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.
(2)The three months and year ended December 31, 2023 include costs related to the proposed merger with Physicians Realty Trust, which are primarily comprised of legal, accounting, tax, and other costs that were incurred prior to year-end, partially offset by termination fee income associated with Graphite Bio, Inc., for which the lease terms have been modified to accelerate expiration of the lease to December 2024. Termination fee income is included in rental and related revenues on the Consolidated Statements of Operations.
(3)The three months and year ended December 31, 2022 include $7 million of charges incurred in connection with the downsizing of the Company’s corporate headquarters in Denver, Colorado, which are included in general and administrative expenses in the Consolidated Statements of Operations. The year ended December 31, 2022 also includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) $14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an outpatient medical building and (ii) a $23 million gain on sale of a hospital under a direct financing lease. The three months and years ended December 31, 2023 and 2022 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.
(4)The three months and year ended December 31, 2022 include $32 million of severance-related charges associated with the departures of our former Chief Executive Officer and former Chief Legal Officer and General Counsel in the fourth quarter of 2022. These expenses are included in general and administrative expenses in the Consolidated Statements of Operations.
(5)Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.
(6)In conjunction with classifying the assets related to the Callan Ridge JV as held for sale as of December 31, 2023, we concluded it was more likely than not that we would realize the future value of certain deferred tax assets generated by the net operating losses of taxable REIT subsidiaries. Accordingly, during the three months and year ended December 31, 2023, we recognized the reversal of a portion of the associated valuation allowance and recognized a corresponding income tax benefit.


Healthpeak Properties, Inc.
Adjusted Funds From Operations
In thousands
 Three Months Ended
December 31,		Year Ended
December 31,
 2023202220232022
FFO as Adjusted applicable to common shares$250,261 $236,473 $978,306 $940,933 
Stock-based compensation amortization expense3,513 1,903 14,480 16,537 
Amortization of deferred financing costs3,088 2,812 11,916 10,881 
Straight-line rents(1)
(1,677)(12,346)(14,387)(49,183)
AFFO capital expenditures(47,332)(33,407)(113,596)(108,510)
Deferred income taxes117 (355)(816)(4,096)
Amortization of above (below) market lease intangibles, net(5,525)(5,851)(25,791)(23,380)
Other AFFO adjustments(7,486)3,536 (9,335)520 
AFFO applicable to common shares194,959 192,765 840,777 783,702 
Distributions on dilutive convertible units and other1,663 1,649 6,581 6,594 
Diluted AFFO applicable to common shares$196,622 $194,414 $847,358 $790,296 
Diluted AFFO per common share$0.36 $0.36 $1.53 $1.45 
Weighted average shares outstanding - diluted AFFO552,810 543,879 552,734 544,637 
_______________________________________
(1)The year ended December 31, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This activity is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.